GO
Loading...

FDA delays decision on Orexigen's obesity drug by 3 months

Nick M. Do | E+ | Getty Images

Orexigen Therapeutics said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug by three months, sending the company's shares down about 19 percent in premarket trading.

The regulator indicated the extension is required to reach an agreement on the post-marketing obligations linked to the evaluation of heart risk related to the drug, contrave, Orexigen said in a statement.

Read MoreMuch-anticipated diet drug in spotlight this week

The regulator, which rejected the drug in 2011, had asked the company to conduct additional trials to assess the potential for heart risk.

An interim analysis of the heart risk study showed that overweight and obese patients receiving contrave did not have a higher heart risk compared with those on a placebo, the company said in November.

If approved, contrave will compete with Vivus' Qsymia and Arena Pharmaceuticals' Belviq, which were approved in 2012.

Qsymia and Belviq have been slugging it out to conquer the weight-loss market, but sales have fallen far short of expectations.

Some analysts blame marketing strategies for the lower-than-expected sales of the two drugs, while others say physicians are yet to be convinced that new drugs have overcome the safety issues that caused the withdrawal of earlier diet drugs.

Qsymia and Belviq have been plagued by safety concerns, ranging from depression and anxiety to heart risks and potential harm to fetuses in pregnant patients.

Read MoreDiet drinks linked with heart disease, death

Orexigen, which has licensed the North American rights to contrave to Takeda Pharmaceutical, entered into a agreement with Sanofi in November to manufacture the drug outside North America.

Contrave is also currently being evaluated by European regulators.

Over one-third of adults in the United States are obese, according to the Centers for Disease Control and Prevention.

San Diego-based Orexigen's shares closed at $6.81 on the Nasdaq on Tuesday. (Click here for the latest quote.)

By Reuters

Contact Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More